Hyloris reports full year results for 2022 & provides business outlook
Strong R&D progress & attractive commercial deals, including additional Tranexamic Acid RTU out-licensing deals Potential U.S. market approval for Maxigesic® IV in H2 2023 Promising new product candidates driving innovation and on track for a …